Queensland Mining Corporation Limited (ASX:QMN) is pleased to report new high-grade copper discovery on Horseshoe ML and Duck Creek EPM.
South Boulder Mines Limited (ASX:STB) is pleased to announce that Dr Chris Gilchrist has agreed to join the Board' as a non-executive Director with immediate effect.
FINANCE VIDEO: Augur Resources (ASX:AUK) Managing Director Grant Kensington presented live to Sydney's Capital Markets at Investorium.tv, regarding the company focus on gold and copper at its Indonesian projects as well as within the Lachlan Fold Belt of central NSW.
FINANCE VIDEO: Proto Resources (ASX:PRW) Joint Managing Director Andrew Mortimer presented live to Sydney's Capital Markets at Investorium.tv, regarding nickel-cobalt and iron ore development and exploration of copper and nickel sulphide targets across Australia.
FINANCE VIDEO: Botswana Metals (ASX:BML) Executive Chairman Pat Volpe presents live to the Capital Markets in Sydney at Investorium.tv, regarding capitalising on base and precious metal opportunites and advanced projects in Botswana.
FINANCE VIDEO: Queensland Mining Corporation (ASX:QMN) Managing Director and Deputy Chairman, Howard Renshaw, presented live to the Sydney Capital Markets at Investorium.tv, regarding QMC's copper gold play and development activities in the Cloncurry region of north west Queensland.
Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.
